698P Interim results from a phase I/II study of HPN328, a tri-specific, half-life (T1/2) extended DLL3-targeting T cell engager in patients (pts) with small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN)

Noura J. Choudhury, Himisha Beltran, Hirva Mamdani et al.|Annals of Oncology|2023

Cited by 10